You searched for "evidence"
Age does not impact risk for urethroplasty complications after TIP repair of hypospadias
This paper is evidence of an increasing trend (especially in the USA) to lower the age at which hypospadias repair is undertaken. The current generalised best accepted age to repair hypospadias is between 6-18 months, which was reduced in the...
Onabotulinum toxin A (BTX) not helpful for chronic scrotal pain
It is refreshing to read a report on negative outcomes as it reinforces the honesty that is often lacking with the well-known publication bias in medical publications. It is also not common to come across surgical randomised controlled trials (RCTs)...
To clamp or not to clamp – outcomes of the CLOCK trial for robotic partial nephrectomy
The benefits of partial over radical nephrectomy are well established. The CLOCK trial (CLamp vs. Off Clamp the Kidney during robotic partial nephrectomy) was designed as a multicentre, randomised controlled trial to generate evidence on the role of the off-clamp...
Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...
Can you boost your bladder with vitamin D?
Bladder overactivity is a common problem affecting the social functioning of children. Overactive bladder dry (OAB-dry) is a term (one not utilised by the International Children’s Continence Society) and refers to patients who are experiencing frequency, urgency and nocturia symptoms...
All biochemical recurrences are equal, but some are more equal than others
Despite significant technological advancements, radical prostatectomy (RP) and radiotherapy (RT) are not always effective in curing localised prostate cancer (PCa). Many patients experience a rise in prostate-specific antigen (PSA), known as biochemical recurrence (BCR), leading to considerable anxiety and a...medac Pharma launch education platform, medac Academy
medac Pharma have launched a new digital education platform for UK healthcare professionals, medac Academy.NICE has recently moved the IRE guidelines from ‘Research Only’ to ‘Special Arrangements’
This recent update provides increased access to the AngioDynamics NanoKnife IRE ablation...NOVOGLAN – Conservative Phimosis Management
iMEDicare are pleased to introduce Novoglan, an evidence-based, non-surgical solution for adult phimosis, now available as a reimbursable outpatient treatment under the NHS OPCS-4 code N30.5 (Stretching of the Prepuce), which maps to HRG LB56A. This presents an exciting opportunity...
Management dilemma for very high-risk non–muscle-invasive bladder cancer
The European Association of Urology (EAU) guidelines recommend upfront radical cystectomy (RC) for very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC). However, real-world adoption is limited, as most patients are reluctant to undergo immediate bladder removal. The EAU 2021 risk model...The Future of Prostate Cancer Imaging: What’s Next?
The pioneering charity Prostate Cancer Research convened industry leaders, NHS experts and patients for a webinar exploring how artificial intelligence (AI) is transforming prostate cancer imaging and clinical pathways. The session provided valuable insights for healthcare professionals seeking innovative approaches...
